Sector
PharmaceuticalsOpen
₹2,701Prev. Close
₹2,743.3Turnover(Lac.)
₹648.09Day's High
₹2,737.9Day's Low
₹2,693.952 Week's High
₹3,14852 Week's Low
₹1,921Book Value
₹144.21Face Value
₹10Mkt Cap (₹ Cr.)
45,907.34P/E
54.83EPS
49.99Divi. Yield
1.1729 Oct 2024
12:00 AM
Dividend
Dividend Amount: 12
Record Date: 07 Nov, 2024
17 May 2024
12:00 AM
AGM
Announcement Date: 17 May, 2024
26 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
Here are some of the stocks that may see significant price movement today: GIC Re, GSK Pharma, Godfrey Philips, etc.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 169.41 | 169.41 | 169.41 | 169.41 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,614.69 | 1,583.59 | 2,508.21 | 1,327.71 |
Net Worth | 1,784.1 | 1,753 | 2,677.62 | 1,497.12 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 3,217.5 | 2,920.47 | 3,224.68 | 2,871.68 |
yoy growth (%) | 10.17 | -9.43 | 12.29 | -1.07 |
Raw materials | -1,295.73 | -1,249.36 | -1,307.86 | -1,240.75 |
As % of sales | 40.27 | 42.77 | 40.55 | 43.2 |
Employee costs | -610.23 | -616.16 | -628.55 | -523.39 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 761.86 | 625.82 | 646.99 | 523.78 |
Depreciation | -68.18 | -78.6 | -82.67 | -37.98 |
Tax paid | -396.86 | -166.53 | -212.44 | -189.59 |
Working capital | 776.94 | 111.42 | 187.45 | -365.58 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 10.17 | -9.43 | 12.29 | -1.07 |
Op profit growth | 26.44 | -9.21 | 29.5 | 21.07 |
EBIT growth | 21.37 | -3.66 | 24.68 | 12.53 |
Net profit growth | 372.78 | 224.9 | -68.73 | 4.51 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 3,453.71 | 3,251.72 | 3,278.03 | 2,925.6 | 3,224.38 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 3,453.71 | 3,251.72 | 3,278.03 | 2,925.6 | 3,224.38 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 122.59 | 103.71 | 1,401.31 | 181.46 | 79.01 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,767.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,960.5 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.8 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,185.8 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,439.5 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
D Sundaram
Company Sec. & Compli. Officer
A A Nadkarni
Independent Director
P V Bhide
Independent Director
A N Roy
Non Executive Director
Subesh Williams
Chairperson
Renu S Karnad
Independent Director
Sunita Maheshwari
Independent Director
Manu Anand
Managing Director
Bhushan Akshikar
Whole Time Director & CFO
J. Chandy
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Glaxosmithkline Pharmaceuticals Ltd
Summary
GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as Glindia Limited in November, 1924. The Company s name was changed to Glaxo (India) Limited from Glindia Limited in year 1987 and further to GlaxoSmithKline Pharmaceuticals Limited from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices, a manufacturing facility at Nashik in Maharashtra, 22 contract manufacturing organisations (CMOs) with regional and sales hubs across India. The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.The Companys portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines, for the prevention of Hepatitis A, Hepatitis B, Invasive Disease caused by H, Influenza, Chickenpox, Diphtheria, Pertussis, Tetanus, Rotavirus, Cervical Cancer and Others. They have two manufacturing units in India, located at Nashik and Thane. Also, they have a clinical development centre in Bangalore. During year 1956, the Company began primary
Read More
What is the Glaxosmithkline Pharmaceuticals Ltd share price today?
The Glaxosmithkline Pharmaceuticals Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹2709.9 today.
What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Glaxosmithkline Pharmaceuticals Ltd is ₹45907.34 Cr. as of 09 May ‘25
What is the PE and PB ratio of Glaxosmithkline Pharmaceuticals Ltd?
The PE and PB ratios of Glaxosmithkline Pharmaceuticals Ltd is 54.83 and 27.73 as of 09 May ‘25
What is the 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Glaxosmithkline Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Glaxosmithkline Pharmaceuticals Ltd is ₹1921 and ₹3148 as of 09 May ‘25
What is the CAGR of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd's CAGR for 5 Years at 13.80%, 3 Years at 21.54%, 1 Year at 36.21%, 6 Month at 7.11%, 3 Month at 28.11% and 1 Month at 0.55%.
What is the shareholding pattern of Glaxosmithkline Pharmaceuticals Ltd?
The shareholding pattern of Glaxosmithkline Pharmaceuticals Ltd is as follows:
Promoters - 75.00 %
Institutions - 12.31 %
Public - 12.69 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
